L
LYSOGENE
Clinical stage biotechnology company pioneering in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need
About LYSOGENE
Lysogene is a biopharmaceutical company dedicated to developing gene therapies for central nervous system (CNS) diseases, particularly in pediatric patients. The company operates in the healthcare and biotechnology sectors, focusing on rare genetic disorders. Lysogene's business model revolves around advancing clinical trials and forming strategic research collaborations, such as with the Weizmann Institute of Science. Revenue generation is primarily through partnerships, licensing agreements, and potential future product sales. The company is actively involved in clinical trials, including the AAVance trial for MPS IIIA and the LYS GM101 trial for GM1 Gangliosidosis, aiming to bring transformative therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Neuilly-sur-Seine, France
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sofinnova Investments
Bpifrance
Sofinnova Partners
Novo Seeds
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about LYSOGENE on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LYSOGENE on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.